| UNITED
STATES |
OMB APPROVAL |
| SECURITIES
AND EXCHANGE COMMISSION |
OMB Number: 3235-0058 |
| Washington,
D.C. 20549 |
Expires: September 30, 2028 Estimated average burden hours per response ...............2.50 |
| |
SEC FILE NUMBER |
| FORM
12b-25 |
001-41141 |
| |
CUSIP NUMBER |
| NOTIFICATION
OF LATE FILING |
45824Q88 |
| (Check
one): |
☐ Form
10-K |
☐ Form
20-F |
☐ Form
11-K |
|
| |
☒
Form 10-Q |
☐ Form
10-D |
☐ Form
N-CEN |
☐ Form
N-CSR |
| |
For
Period Ended: September 30, 2026 |
| |
☐ |
Transition Report
on Form 10-K |
| |
☐ |
Transition Report on Form
20-F |
| |
☐ |
Transition Report on Form
11-K |
| |
☐ |
Transition Report on Form
10-Q |
| |
|
For the
Transition Period Ended: _______________________ |
| Read
Instruction (on back page) Before Preparing Form. Please Print or Type. |
| Nothing
in this Fo shall be construed to imply that the Commission has verified any information contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
Glucotrack,
Inc.
Full
Name of Registrant
Former
Name if Applicable
301
Rte. 17 North, Ste. 800
Address
of Principal Executive Office (Street and Number)
Rutherford,
NJ, 07970
City,
State and Zip Code
| SEC
1344 (01-19) |
Potential
persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays
a currently valid OMB control number. |
Board
of Governors of the Federal Reserve System
OMB Number
7100-0091 Approval expires February 28,
2027
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
| |
(a) |
The
reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense; |
| |
|
|
| ☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
| |
|
|
| |
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
The
Company was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 within the prescribed time period
without unreasonable effort or expense. The delay primarily relates to the completion of accounting analyses, valuation procedures, and
financial statement disclosures associated with derivative liabilities and embedded derivative features contained in certain financing
instruments issued by the Company.
Management
is working with external valuation specialists and accounting advisors to complete the fair value measurements and related accounting
analyses required under ASC 815, Derivatives and Hedging, and ASC 820, Fair Value Measurement. The valuation process requires significant
judgment regarding volatility assumptions, probability-weighted outcomes, expected term assumptions, market inputs, and other factors
relevant to the determination of fair value.
Additional
time is required to complete these analyses, finalize the accounting treatment, complete management review procedures, and allow the
Company’s independent registered public accounting firm sufficient time to complete its review of the Company’s interim financial
statements and related disclosures.
The
Company expects to file its Form 10-Q within the five-calendar-day extension period provided by Rule 12b-25. The Company does not currently
expect that the delay will result in any material change to previously announced financial information, although its financial statements
remain subject to completion and review.
PART
IV — OTHER INFORMATION
| (1) | Name
and telephone number of person to contact in regard to this notification |
| Erik
Emerson |
|
201 |
|
842-7715 |
| (Name) |
|
(Area
Code) |
|
(Telephone
Number) |
| (2) | Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed?
If answer is no, identify report(s). X Yes ☐ No |
| (3) | Is
it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof? |
| | | |
| | | ☒
Yes ☐ No |
If
so, the explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made follows:
The
merger with Lokahi and the financing transactions occurred during the quarter ended September 30, 2026 resulted in additional operating
and financing expenses from the corresponding period in 2025. We anticipate operating expenses increasing by approximately $4.6 million
from approximately $12.6 million to approximately $17.2 million. We also anticipate net financing related expenses increasing by approximately
$8.7 million from approximately from approximately $3.1 million to approximately $11.8 million. As a result, we anticipate that the net
loss increasing approximately $13.3 million to $29.0 million.
Forward
looking statements
This
Notification of Late Filing contains forward-looking statements, including statements regarding the Company’s efforts to complete
the accounting analysis and valuation of derivative liabilities, finalize its financial statements, and file its Quarterly Report on
Form 10-Q within the extension period provided under Rule 12b-25. Actual results may differ materially from those expressed or implied
by these forward-looking statements due to risks and uncertainties, including the outcome of the Company’s valuation procedures,
ongoing review by management and auditors, the identification of additional accounting issues, and other factors beyond the Company’s
control. The Company undertakes no obligation to update any forward-looking statements contained herein except as required by law.
GLUCOTRACK,
INC.
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date
November 16, 2026 |
By |
/s/ Erik Emerson |
| |
|
Erik
Emerson, CEO |